Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

liver, lung and lymph node metastases. The duration of response, independently reviewed, ranged from 7.1 weeks to 30.0 weeks. The median time to progression in the treated population was 5.9 weeks. The adverse events were manageable, predictable and consistent with those seen in the Phase I trials of ispinesib. The most common grade 3/4 adverse events observed were neutropenia, febrile neutropenia and neutropenic sepsis.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial evaluating ispinesib in combination with capecitabine is closed to enrollment. Final data from this trial are expected in 2007.

Under a November 2006 amendment to its collaboration and license agreement with GSK, Cytokinetics has assumed responsibility for the costs and activities associated with the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK s option to resume responsibility for some or all development and commercialization activities associated with each of these novel drug candidates. Cytokinetics plans to conduct, at its expense, a focused development program for ispinesib in breast cancer specifically designed to supplement the broad series of Phase I and Phase II clinical trials sponsored by GSK that have demonstrated clinical activity in the treatment of patients with metastatic breast cancer and that have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics.

The NCI has sponsored six additional Phase II clinical trials, evaluating the potential efficacy of ispinesib in an array of different tumor types. Enrollment has been closed for
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/19/2014)... Dec. 18, 2014 Capnia, Inc. (NASDAQ: ... of medical diagnostics based on its proprietary Sensalyze™ ... today announced financial results for the third quarter ... "Following the completion of our initial public ... maximize the recently initiated CoSense® commercial launch," said ...
(Date:12/19/2014)... Baptist Health Lexington is the first facility in ... with Electrophysiology Services (EPS) Accreditation status from the Society of ... most common cardiac arrhythmia and has become recognized as a ... and possible death. More than 5 million patients in ... the numbers are rapidly increasing as the population ages. ...
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
(Date:12/22/2014)... 2014 The holidays are here, and with ... Many may be thinking about how to enjoy these events ... weeks. Health Republic Insurance of New York has compiled some ... to provide some smart ideas to enjoy the holiday festivities ... arriving at a holiday gathering over-hungry , Have a light ...
(Date:12/22/2014)... New York, NY (PRWEB) December 22, 2014 ... out 2014 stronger than ever, having invested more ... post-9/11 injured service members, veterans and their families. ... today for nearly a dozen nonprofits, helping with: ... peer-support; nursing scholarships; and life-coaches for severely injured ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 TheHardwareCity.com now ... glove with many useful features. Customers of the large ... have the new gloves delivered to their home or ... and hand tools that incorporate heavy duty magnets, which ... Glove allows workers to store metal parts on the ...
(Date:12/22/2014)... December 21, 2014 A substantial ... chest computed tomography (CT) to evaluate abnormal findings ... including cancer, according to a new study published ... said the findings show that radiologist recommendations for ... contributions to patient care. , RAIs, which have ...
Breaking Medicine News(10 mins):Health News:Health Republic Insurance of New York Offers Five Simple Tips to Eat Healthy During the Holidays 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3
... Russian President Vladimir Putin to Adopt a National ... Plan ... Cancer, a cancer,patient advocacy group in Russia, today launched an effort ... in Russia to innovative and effective treatments, including,diagnostic procedures and the ...
... Public Services, Inc.,a subsidiary of SAP AG (NYSE: ... vice,president of its U.S. healthcare practice. The appointment ... initiatives to improve the quality and delivery of,healthcare ... for growing,SAP,s business in the U.S. healthcare sector ...
... Joyce Erony Joins Board of Directors -, PALO ... device company that is developing a new category of ... that,it has raised $21 million in a Series C ... also announced that Joyce Erony,managing director of Signet Healthcare ...
... FRANKLIN LAKES, N.J., Feb. 4 Medco Health,Solutions, Inc. ... and,full-year 2007 financial results in a press release before ... the release, management will hold a conference call to ... a.m. ET., To access the live conference call ...
... is the First and Only Inhaled Corticosteroid approved for ... Once-Daily dosing in Children as Young as Age 4, ... today announced that the U.S. Food and Drug,Administration (FDA) has ... for the maintenance treatment of,asthma as a preventive therapy in ...
... Cherries, May Help Protect Your Heart, LANSING, Mich., ... universal mantras for promoting heart-health during February,American Heart Month. ... eating red to protect our hearts. Americans are encouraged ... the first-ever National,Eat Red Week, Feb. 4-10., Why ...
Cached Medicine News:Health News:Movement Against Cancer, a Cancer Patient Advocacy Group in Russia, Launches an Effort to Inform Russian Authorities and the Public About Inadequate Access of Innovative and Effective Cancer Treatments for Cancer Patients in Russia 2Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 2Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 3Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 4Health News:SAP Names David Corbett as Vice President of U.S. Healthcare Practice 5Health News:PEAK Surgical, Inc. Closes $21 Million Series C Financing 2Health News:Medco Announces Date for Fourth-Quarter and Full-Year 2007 Financial Results 2Health News:FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 2Health News:FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 3Health News:FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 4Health News:FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 5Health News:FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11 6Health News:Celebrate American Heart Month by Eating Red 2Health News:Celebrate American Heart Month by Eating Red 3
The DEI 750 MD from Optronics is a surgical 3 CCD color microscope camera with a 10 meter head cable. Easily mounts on your microscopes C-mount adapter and is the best choice for your surgical imagin...
... The Optronics QuantiFIRE represents the ... in advanced scientific grade CCD imaging ... Thermoelectrically Cooled Monochrome CCD camera developed ... low-light, darkfield, fluoresence or NIR imaging ...
The Optronics MacroFIRE represents the latest innovation from the world leader in advanced scientific grade CCD imaging for microscopy. MacroFIRE is a versatile CCD camera developed exclusively for c...
... is an Ancient Chinese Method of enhancing health ... fosters health and healing by promoting a smooth ... that the body can heal itself. However, it ... Soleil experts have spent years mastering Qigong and ...
Medicine Products: